← 返回

人 CD8-iTreg 通过释放 Granzyme-K (+) 超分子攻击颗粒成为强效 GVHD 抑制细胞和杀肿瘤效应细胞

英文原题:Human CD8-iTreg are potent GVHD suppressors and tumoricidal effectors by release of Granzyme-K (+) Supramolecular Attack Particles.

查看英文原题

Human CD8-iTreg are potent GVHD suppressors and tumoricidal effectors by release of Granzyme-K (+) Supramolecular Attack Particles.

PubMed 2026/06/23(内容时间) bioRxiv

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

调节性CD8+ T细胞(CD8+ Treg)是一种独特但研究不足的T细胞亚群,兼具免疫抑制和细胞溶解能力。本研究对诱导型人CD8+ Treg(CD8-iTreg)进行表征,该细胞由外周血CD8+ CD25− T细胞经抗CD3ε单克隆抗体负载的人工抗原呈递细胞、IL-2、TGF-β和雷帕霉素诱导产生。CD8-iTreg分化为稳定、高增殖的双功能细胞群,其抑制活性与CD4-iTreg相当,同时保留了与常规CD8细胞毒性T淋巴细胞(CTL)相似的细胞毒能力。多参数光谱流式细胞术和单细胞RNA测序显示其具有独特免疫调节特征:总体呈Treg样表达谱,以组织驻留标志物CD103为特征,FoxP3、HELIOS、CD25、CD39、CTLA-4、CCR4和IL-10等经典Treg标志物升高,促炎细胞因子降低。

独特细胞毒程序的标志是颗粒酶K(GzmK)和血小板反应蛋白4(Tsp-4)升高;Tsp-4是一种在活化CD8+ T细胞中上调的血小板反应蛋白家族细胞外基质糖蛋白。细胞溶解主要由穿孔素(Prf)和多种装载于Tsp-4超分子攻击颗粒(SMAP)中的颗粒酶介导,GzmK则同时参与细胞毒和免疫抑制功能。经抗CD19 scFv CAR(CAR19)转导后,与CAR19-CTL相比,CAR19+ CD8-iTreg在体内抗肿瘤疗效更优;在CD19+ Nalm-6人白血病异种移植模型中显著降低肿瘤负荷并延长生存,同时维持较低促炎细胞因子生成。在伴残留人白血病的异种移植物抗宿主病(GVHD)模型中,CAR19 CD8-iTreg抑制了GVHD相关死亡并控制肿瘤生长,且未增加全身炎症。

总之,这些发现支持以CD8-iTreg为基础的CAR疗法:可保留强效抗白血病活性,同时限制传统CAR-T 细胞的炎症毒性,特别适用于自身免疫和异基因免疫相关疾病。一句话总结:CD8-iTreg通过释放含颗粒酶K的Tsp-4+ SMAP,同时发挥肿瘤杀伤和免疫调节作用。

展开英文摘要原文

UNLABELLED: Regulatory CD8 + T-cells (CD8 + Treg) are a distinct yet understudied T-cell subset capable of simultaneous immunosuppression and cytolysis.

Here, we characterized induced human CD8 + Treg (CD8-iTreg) generated from peripheral blood CD8 + CD25 T-cells using anti-CD3e mAb-loaded artificial antigen presenting cells, IL-2, TGF , and Rapamycin. These CD8-iTreg differentiated into a stable, highly proliferative bifunctional population with suppressive activity comparable to CD4-iTreg while retaining cytolytic capacity similar to conventional CD8 cytotoxic T lymphocytes (CTL). Multi-parameter spectral flow cytometry and single-cell RNA-seq revealed a distinct immunoregulatory signature: a predominantly Treg-like profile marked by tissue-residency marker CD103 with increased canonical Treg markers (FoxP3, HELIOS, CD25, CD39, CTLA-4, CCR4, and IL-10) and reduced pro-inflammatory cytokines.

A unique cytotoxic program was marked by elevated Granzyme-K (GzmK) and Thrombospondin-4 (Tsp-4), a thrombospondin family extracellular matrix glycoprotein upregulated in activated CD8+ T-cells. Cytolysis was primarily mediated by Perforin (Prf) and multiple Granzymes packaged into Tsp-4 supramolecular attack particles (SMAPs), with GzmK contributing to both cytotoxic and suppressive functions.

After anti-CD19scFv CAR (CAR19) transduction, CAR19 + CD8-iTreg showed superior in vivo anti-tumor efficacy compared with CAR19-CTLs, significantly reducing tumor burden and prolonging survival in a CD19 + Nalm-6 human leukemia xenograft model while maintaining low pro-inflammatory cytokine production. In a xenogeneic graft-versus-host disease (GVHD) model with residual human leukemia, CAR19 CD8-iTreg inhibited GVHD lethality and controlled tumor growth without increasing systemic inflammation.

Together, these findings support CD8-iTreg-based CAR therapies as a strategy to retain potent anti-leukemic activity while limiting inflammatory toxicities of conventional CAR T-cells, properties particularly beneficial in treating auto- and allo-immune diseases. ONE SENTENCE SUMMARY: CD8-iTreg drive parallel tumoricidal and immunoregulatory functions mediated by releasing Tsp-4 + SMAPs containing granzyme K.

论文信息

作者
Larson JH、Compeer EB、Dougherty PR、Smith K、Zaiken MC、Margaritaki O、Kopp B、Jin S
文献类型
预印本
期刊
bioRxiv : the preprint server for biology2026 Jun 23
原文标识
PubMed 42395370 · DOI 10.64898/2026.06.18.731665